The role of leukotrienes in immunopathogenesis of rheumatoid arthritis

Modern Rheumatology

Volumn 24, Issue 2, 2014, Pages 225-235

  Yousefi, Bahman ^a   Jadidi Niaragh, Farhad ^a   Azizi, Gholamreza ^b   Hajighasemi, Fatemeh ^c   Mirshafiey, Abbas ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ALBORZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHED UNIVERSITY   (Iran)

Author keywords

Leukotriene; RA immunopathogenesis; Rheumatoid arthritis (RA)

Indexed keywords

ANTIRHEUMATIC AGENT; ARACHIDONIC ACID; BIOLOGICAL RESPONSE MODIFIER; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUKOTRIENE; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR;

AEROBIC METABOLISM; ARACHIDONIC ACID METABOLISM; BIOACCUMULATION; CLINICAL TRIAL (TOPIC); DISEASE COURSE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TISSUE INJURY;

ARTHRITIS, RHEUMATOID; HUMANS; INFLAMMATION; LEUKOTRIENES; RECEPTORS, LEUKOTRIENE;

EID: 84905023521     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.854056     Document Type: Review

References (121)

1. Firestein G S.Avolving concepts of rheumatoid arthritis. Nature. 2003 ; 423 (6937) : 356-61.
2. Noss E H, Brenner M B.The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol Rev. 2008 ; 223 : 252-70.
3. Serhan C N, Yacoubian S , Yang R.A nti-inflammatory and proresolving lipid mediators. Annu Rev Pathol. 2008 ; 3 : 279-312.
4. Shimizu T.Lipid mediators in health and disease:enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol. 2009 ; 49 : 123-50.
5. Gursel T , Firat S , Ercan ZS. Increased serum leukotriene B4 level in the active stage of rheumatoid arthritis in children. Prostaglandins Leukot Essent Fatty Acids. 1997 ; 56 (3) : 205-7.
6. Grignani G , Zucchella M , Belai B N, Brocchieri A , Saporiti A , Cherie Ligniere EL. Levels of different metabolites of arachidonic acid in synovial fl uid of patients with arthrosis or rheumatoid arthritis. Minerva Med. 1996 ; 87 (3) : 75-9.
7. Bailie M B, Standiford T J, Laichalk L L, Coffey MJ , Strieter R , Peters-Golden M.Leukotriene-deficient mice manifest enhanced lethality from Klebsiella pneumonia in association with decreased alveolar macrophage phagocytic and bactericidal activities. JImmunol. 1996 ; 157 (12) : 5221-4.
8. Benjamim CF , Canetti C , Cunha FQ , Kunkel SL , Peters-Golden M.Opposing and hierarchical roles of leukotrienes in local innate immune versus vascular responses in a model of sepsis. JImmunol. 2005 ; 174 (3) : 1616-20.
9. Samuelsson B , Dahlen S E, Lindgren J A, Rouzer C A, Serhan C N.Leukotrienes and lipoxins:structures, biosynthesis, and biological effects. Science. 1987 ; 237 (4819) : 1171-6.
10. Michel AA , Steinhilber D , Werz O.Development of a method for expression and purification of the regulatory C2-like domain of human 5-lipoxygenase. Protein Expr Purif. 2008 ; 59 (1) : 110-6.
11. Maas R L, Ingram C D, Taber D F, Oates J A, Brash A R.Stereospecific removal of the DR hydrogen atom at the 10-carbon of arachidonic acid in the biosynthesis of leukotriene A4 by human leukocytes. JBiol Chem. 1982 ; 257 (22) : 13515-9.
12. Shimizu T , Radmark O , Samuelsson B.Enzyme with dual lipoxygenase activities catalyzes leukotriene A4 synthesis from arachidonic acid. Proc Natl Acad Sci USA. 1984 ; 81 (3) : 689-93.
13. A bramovitz M , W ong E , Cox M E, Richardson C D, Li C , Vickers PJ. 5-Lipoxygenase-Activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. Eur J Biochem. 1993 ; 215 (1) : 105-11.
14. Neu I , Mallinger J , W ildfeuer A , Mehlber L.Leukotrienes in the cerebrospinal fl uid of multiple sclerosis patients. Acta Neurol Scand. 1992 ; 86 (6) : 586-7.
15. Brock TG , Paine R III , Peters-Golden M.Localization of 5-lipoxygenase to the nucleus of unstimulated rat basophilic leukemia cells. JBiol Chem. 1994 ; 269 (35) : 22059-66.
16. Woods JW , Evans JF , Ethier D , Scott S , Vickers PJ , Hearn L , et al. 5-Lipoxygenase and 5-lipoxygenase-Activating protein are localized in the nuclear envelope of activated human leukocytes. JExp Med. 1993 ; 178 (6) : 1935-46.
17. Clark SR , Coffey M J, Maclean R M, Collins P W, Lewis M J, Cross AR , et al. Characterization of nitric oxide consumption pathways by normal, chronic granulomatous disease and myeloperoxidasedeficient human neutrophils. JImmunol. 2002 ; 169 (10) : 5889-96.
18. Rouzer C A, Matsumoto T , Samuelsson B.Single protein from human leukocytes possesses 5-lipoxygenase and leukotriene A4 synthase activities. Proc Natl Acad Sci USA. 1986 ; 83 (4) : 857-61.
19. Lewis R A, Austen K F, Soberman R J.Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. NEngl J Med. 1990 ; 323 (10) : 645-55.
20. Penrose JF. LTC4 synthase. Enzymology, biochemistry, and molecular characterization. Clin Rev Allergy Immunol. 1999 ; 17 (1-2) : 133-52.
21. Bernstrom K , Orning L , Hammarstrom S.Gamma-glutamyl transpeptidase, Aleukotriene metabolizing enzyme. Methods Enzymol. 1982 ; 86 : 38-45.
22. Nagaoka I , Yamada M , Kira S , Yamashita T.Comparative studies on the leukotriene D4-metabolizing enzyme of different types of leukocytes. Comp Biochem Physiol B.1988 ; 89 (2) : 375-80.
23. Raulf M , Konig W , Koller M , Stuning M.Release and functional characterization of the leukotriene D4-metabolizing enzyme (dipeptidase) from human polymorphonuclear leucocytes. Scand J Immunol. 1987 ; 25 (3) : 305-13.
24. Haeggstrom JZ , Kull F , Rudberg PC , Tholander F , Thunnissen MM. Leukotriene A4 hydrolase. Prostaglandins Other Lipid Mediat. 2002 ; 68-69 : 495-510.
25. Maclouf J , Antoine C , Henson PM , Murphy RC. Leukotriene C4 formation by transcellular biosynthesis. Ann N Y Acad Sci. 1994 ; 714 : 143-50.
26. Maclouf J , Sala A , Rossoni G , Berti F , Muller-Peddinghaus R , Folco G.Consequences of transcellular biosynthesis of leukotriene C4 on organ function. Haemostasis. 1996 ; 26 (Suppl 4) : 28-36.
27. Ciana P , Fumagalli M , Trincavelli M L, Verderio C , Rosa P , Lecca D , et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J.2006 ; 25 (19) : 4615-27.
28. Lynch KR , O'Neill GP , Liu Q , Im DS , Sawyer N , Metters KM , et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999 ; 399 (6738) : 789-93.
29. Mellor E A, Maekawa A , Austen K F, Boyce J A.Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human maStCells. Proc Natl Acad Sci USA. 2001 ; 98 (14) : 7964-9.
30. Sarau H M, Ames R S, Chambers J , Ellis C , Elshourbagy N , Foley J J, et al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol. 1999 ; 56 (3) : 657-63.
31. Nielsen C K, Campbell J I, Ohd J F, Morgelin M , Riesbeck K , Landberg G , et al. A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. Cancer Res. 2005 ; 65 (3) : 732-42.
32. Heise C E, O'D owd B F, Figueroa D J, Sawyer N , Nguyen T , Im D S, et al. Characterization of the human cysteinyl leukotriene 2 receptor. JBiol Chem. 2000 ; 275 (39) : 30531-6.
33. Sjostrom M , Johansson AS , Schroder O , Qiu H , Palmblad J , Haeggstrom JZ. Dominant expression of the CysLT2 receptor accounts for calcium signaling by cysteinyl leukotrienes in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol. 2003 ; 23 (8) : e37-41.
34. Lecca D , Trincavelli ML , Gelosa P , Sironi L , Ciana P , Fumagalli M , et al. The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair. PLoS One. 2008 ; 3 (10) : e3579.
35. Communi D , Janssens R , Suarez-Huerta N , Robaye B , Boeynaems JM. Advances in signalling by extracellular nucleotides. The role and transduction mechanisms of P2Y receptors. Cell Signal. 2000 ; 12 (6) : 351-60.
36. Stucky CL , Medler KA , Molliver DC. The P2Y agonist UTP activates cutaneous afferent fibers. Pain. 2004 ; 109 (1-2) : 36-44.
37. Haynes SE , Hollopeter G , Yang G , Kurpius D , Dailey ME , Gan WB , et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat Neurosci. 2006 ; 9 (12) : 1512-9.
38. Koizumi S , Shigemoto-Mogami Y , Nasu-Tada K , Shinozaki Y , Ohsawa K , Tsuda M , et al. UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature. 2007 ; 446 (7139) : 1091-5.
39. Back M , Bu DX , Branstrom R , Sheikine Y , Yan ZQ , Hansson GK. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci USA. 2005 ; 102 (48) : 17501-6.
40. Qiu H , Johansson AS , Sjostrom M , Wan M , Schroder O , Palmblad J , et al. Differential induction of BLT receptor expression on human endothelial cells by lipopolysaccharide, cytokines, and leukotriene B4. Proc Natl Acad Sci USA. 2006 ; 103 (18) : 6913-8.
41. Toda A , Yokomizo T , Shimizu T.Leukotriene B4 receptors. Prostaglandins Other Lipid Mediat. 2002 ; 68-69 : 575-85.
42. Devchand PR , Keller H , Peters JM , Vazquez M , Gonzalez FJ , Wahli W.The PPARalpha-leukotriene B4 pathway to inflammation control. Nature. 1996 ; 384 (6604) : 39-43.
43. Peres C M, Aronoff DM , Serezani CH , Flamand N , Faccioli LH , Peters-Golden M.Specific leukotriene receptors couple to distinct G proteins to effect stimulation of alveolar macrophage host defense functions. JImmunol. 2007 ; 179 (8) : 5454-61.
44. Jiang Y , Borrelli LA , Kanaoka Y , Bacskai BJ , Boyce JA. CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of maStCells. Blood. 2007 ; 110 (9) : 3263-70.
45. Yokomizo T , Kato K , Terawaki K , Izumi T , Shimizu T.A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. JExp Med. 2000 ; 192 (3) : 421-32.
46. Gagnon L , Girard M , Sullivan A K, Rola-Pleszczynski M.Augmentation of human natural cytotoxic cell activity by leukotriene B4 mediated by enhanced effector-target cell binding and increased lytic efficiency. Cell Immunol. 1987 ; 110 (2) : 243-52.
47. Rola-Pleszczynski M , Gagnon L , Sirois P.Leukotriene B4 augments human natural cytotoxic cell activity. Biochem Biophys Res Commun. 1983 ; 113 (2) : 531-7.
48. Yamaoka K A, Claesson H E, Rosen A.Leukotriene B4 enhances activation, proliferation, and differentiation of human B lymphocytes. JImmunol. 1989 ; 143 (6) : 1996-2000.
49. Wang S , Gustafson E , Pang L , Qiao X , Behan J , Maguire M , et al. A novel hepatointestinal leukotriene B4 receptor. Cloning and functional characterization. JBiol Chem. 2000 ; 275 (52) : 40686-94.
50. Haneda Y, Hasegawa S, Hirano R, Hashimoto K, Ohsaki A, Ichiyama T.Leukotriene D(4) enhances tumor necrosis factor-Alpha-induced vascular endothelial growth factor production in human monocytes/macrophages. Cytokine. 2011. [Epub ahead of print].
51. Sala A , Zarini S , Bolla M.Leukotrienes:lipid bioeffectors of inflammatory reactions. Biochemistry (Mosc). 1998 ; 63 (1) : 84-92.
52. Sharma JN, Mohammed LA. The role of leukotrienes in the pathophysiology of inflammatory disorders:is there a case for revisiting leukotrienes as therapeutic targets? Inflammopharmacology. 2006;14(1-2):10-6.
53. Yokomizo T , Izumi T , Shimizu T.Co-expression of two LTB4 receptors in human mononuclear cells. Life Sci. 2001 ; 68 (19-20) : 2207-12.
54. Kato K , Yokomizo T , Izumi T , Shimizu T.Cell-specific transcriptional regulation of human leukotriene B(4) receptor gene. JExp Med. 2000 ; 192 (3) : 413-20.
55. Yokomizo T , Izumi T , Chang K , Takuwa Y , Shimizu T.A G-proteincoupled receptor for leukotriene B4 that mediates chemotaxis. Nature. 1997 ; 387 (6633) : 620-4.
56. Kamohara M , Takasaki J , Matsumoto M , Saito T , Ohishi T , Ishii H , et al. Molecular cloning and characterization of another leukotriene B4 receptor. JBiol Chem. 2000 ; 275 (35) : 27000-4.
57. Tryselius Y , Nilsson NE , Kotarsky K , Olde B , Owman C.Cloning and characterization of cDNA encoding a novel human leukotriene B(4) receptor. Biochem Biophys Res Commun. 2000 ; 274 (2) : 377-82.
58. Mathis SP , Jala VR , Lee DM , Haribabu B.Nonredundant roles for leukotriene B4 receptors BLT1 and BLT2 in inflammatory arthritis. JImmunol. 2010 ; 185 (5) : 3049-56.
59. Hashimoto A , Endo H , Hayashi I , Murakami Y , Kitasato H , Kono S , et al. Differential expression of leukotriene B4 receptor subtypes (BLT1 and BLT2) in human synovial tissues and synovial fl uid leukocytes of patients with rheumatoid arthritis. JRheumatol. 2003 ; 30 (8) : 1712-8.
60. Nicolete R , Rius C , Piqueras L , Jose P J, Sorgi C A, Soares E G, et al. Leukotriene B4-loaded microspheres:A new therapeutic strategy to modulate cell activation. BMC Immunol. 2008 ; 9 : 36.
61. Leibbrandt A , Penninger J M.RANK(L) as a key target for controlling bone loss. Adv Exp Med Biol. 2009 ; 647 : 130-45.
62. Chen ZK , Lv HS , Jiang J.LTB4 can stimulate human osteoclast differentiation dependent of RANKL. Artif Cells Blood Substit Immobil Biotechnol. 2010 ; 38 (1) : 52-6.
63. Sallusto F , Lenig D , Forster R , Lipp M , Lanzavecchia A.Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999 ; 401 (6754) : 708-12.
64. Ott VL , Cambier JC , Kappler J , Marrack P , Swanson BJ. MaStCelldependent migration of effector CD8+ T cells through production of leukotriene B4. Nat Immunol. 2003 ; 4 (10) : 974-81.
65. Goodarzi K , Goodarzi M , Tager AM , Luster AD , Andrian UH. Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat Immunol. 2003 ; 4 (10) : 965-73.
66. Miyahara N , Takeda K , Miyahara S , Matsubara S , Koya T , Joetham A , et al. Requirement for leukotriene B4 receptor 1 in allergeninduced airway hyperresponsiveness. Am J Respir Crit Care Med. 2005 ; 172 (2) : 161-7.
67. Mathis S , Jala V R, Haribabu B.Role of leukotriene B4 receptors in rheumatoid arthritis. Autoimmun Rev. 2007 ; 7 (1) : 12-7.
68. Lee DM , Friend DS , Gurish MF , BenoiStC , Mathis D , Brenner MB. MaStCells:A cellular link between autoantibodies and inflammatory arthritis. Science. 2002 ; 297 (5587) : 1689-92.
69. Griffiths RJ , Smith MA , Roach ML , Stock JL , Stam EJ , Milici AJ , et al. Collagen-induced arthritis is reduced in 5-lipoxygenaseactivating protein-deficient mice. JExp Med. 1997 ; 185 (6) : 1123-9.
70. Canetti CA , Leung BP , Culshaw S , McInnes IB , Cunha FQ , Liew FY. IL-18 enhances collagen-induced arthritis by recruiting neutrophils via TNF-Alpha and leukotriene B4. JImmunol. 2003 ; 171 (2) : 1009-15.
71. McInnes IB. Leukotrienes, maStCells, and T cells. Arthritis Res Ther. 2003 ; 5 (6) : 288-9.
72. Gaff o A , Saag K G, Curtis J R.Treatment of rheumatoid arthritis. A m J Health Syst Pharm. 2006 ; 63 (24) : 2451-65.
73. Feldmann M , Maini R N.A nti-TNF alpha therapy of rheumatoid arthritis:what have we learned?. Annu Rev Immunol. 2001 ; 19 : 163-96.
74. Henderson WR Jr. The role of leukotrienes in inflammation. Ann Intern Med. 1994 ; 121 (9) : 684-97.
75. Massoumi R , Sjolander A.The role of leukotriene receptor signaling in inflammation and cancer. ScientificWorldJournal. 2007 ; 7 : 1413-21.
76. Hikiji H , Takato T , Shimizu T , Ishii S.The roles of prostanoids, leukotrienes, and platelet-Activating factor in bone metabolism and disease. Prog Lipid Res. 2008 ; 47 (2) : 107-26.
77. Ahmadzadeh N , Shingu M , Nobunaga M , Tawara T.Relationship between leukotriene B4 and immunological parameters in rheumatoid synovial fl uids. Inflammation. 1991 ; 15 (6) : 497-503.
78. Cuzzocrea S , Rossi A , Mazzon E , Di P R, Genovese T , Muia C , et al. 5-Lipoxygenase modulates colitis through the regulation of adhesion molecule expression and neutrophil migration. Lab Invest. 2005 ; 85 (6) : 808-22.
79. Cuzzocrea S , Rossi A , Serraino I , Mazzon E , Di P R, Dugo L , et al. 5-Lipoxygenase knockout mice exhibit a resistance to pleurisy and lung injury caused by carrageenan. JLeukoc Biol. 2003 ; 73 (6) : 739-46.
80. Krönke G , Katzenbeisser J , Uderhardt S , Zaiss MM , Scholtysek C , et al. 12/15-Lipoxygenase counteracts inflammation and tissue damage in arthritis. JImmunol. 2009 ; 183 (5) : 3383-9.
81. Serhan CN , Chiang N , Dyke TE. Resolving inflammation:dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008 ; 8 (5) : 349-61.
82. Serhan C N, Jain A , Marleau S , Clish C , Kantarci A , et al. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. JImmunol. 2003 ; 171 (12) : 6856-65.
83. Wen Y , Gu J , Chakrabarti SK , Aylor K , Marshall J , et al. The role of 12/15-lipoxygenase in the expression of interleukin-6 and tumor necrosis factor-Alpha in macrophages. Endocrinology. 2007 ; 148 (3) : 1313-22.
84. Wick G , Knofl ach M , Xu Q.A utoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol. 2004 ; 22 : 361-403.
85. Flamand L , Tremblay MJ , Borgeat P.Leukotriene B4 triggers the in vitro and in vivo release of potent antimicrobial agents. JImmunol. 2007 ; 178 (12) : 8036-45.
86. Chen M , Lam BK , Kanaoka Y , Nigrovic PA , Audoly LP , Austen KF , et al. Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. JExp Med. 2006 ; 203 (4) : 837-42.
87. Hallett M B, W illiams A S.Stopping the traffic:A route to arthritis therapy. Eur J Immunol. 2008 ; 38 (10) : 2650-3.
88. Diaz-Gonzalez F, Alten RH, Bensen WG, Brown JP, Sibley JT, Dougados M, et al. Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(5):628-32.
89. Nigrovic PA , Lee DM. MaStCells in inflammatory arthritis. A rthritis Res Ther. 2005 ; 7 (1) : 1-11.
90. Eklund KK. MaStCells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy. Immunol Rev. 2007 ; 217 : 38-52.
91. Maruotti N , Crivellato E , Cantatore F P, Vacca A , Ribatti D.MaStCells in rheumatoid arthritis. Clin Rheumatol. 2007 ; 26 (1) : 1-4.
92. McLachlan JB , Hart JP , Pizzo SV , Shelburne CP , Staats HF , Gunn MD , et al. MaStCell-derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection. Nat Immunol. 2003 ; 4 (12) : 1199-205.
93. Woolley D E, Tetlow L C.MaStCell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion. Arthritis Res. 2000 ; 2 (1) : 65-74.
94. Harris RR , Carter GW , Bell RL , Moore JL , Brooks DW. Clinical activity of leukotriene inhibitors. Int J Immunopharmacol. 1995 ; 17 (2) : 147-56.
95. Xu S , Lu H , Lin J , Chen Z , Jiang D.Regulation of TNFalpha and IL1beta in rheumatoid arthritis synovial fibroblasts by leukotriene B4. Rheumatol Int. 2010 ; 30 (9) : 1183-9.
96. Lindner SC , Kohl U , Maier TJ , Steinhilber D , Sorg BL. TLR2 ligands augment cPLA2alpha activity and lead to enhanced leukotriene release in human monocytes. JLeukoc Biol. 2009 ; 86 (2) : 389-99.
97. Lefebvre JS, Levesque T, Picard S, Pare G, Gravel A, Flamand L, et al. The extra domain A of fibronectin primes leukotriene biosynthesis and stimulates neutrophil migration through toll-like receptor 4 activation. Arthritis Rheum. 2011;63(6):1527-33.
98. Simmonds R E, Foxwell B M.Signalling, inflammation and arthritis:NF-kappaB and its relevance to arthritis and inflammation. Rheumatology (Oxford). 2008 ; 47 (5) : 584-90.
99. Mankan AK , Lawless MW , Gray SG , Kelleher D , McManus R.NF-kappaB regulation:The nuclear response. JCell Mol Med. 2009 ; 13 (4) : 631-43.
100. Sanchez-Galan E , Gomez-Hernandez A , Vidal C , Martin-Ventura J L, Blanco-Colio LM , Munoz-Garcia B , et al. Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis. Cardiovasc Res. 2009 ; 81 (1) : 216-25.
101. Serezani CH , Lewis C , Jancar S , Peters-Golden M.Leukotriene B4 amplifies NF-kappaB activation in mouse macrophages by reducing SOCS1 inhibition of MyD88 expression. JClin Invest. 2011 ; 121 (2) : 671-82.
102. Abramson S , Edelson H , Kaplan H , Given W , Weissmann G.The neutrophil in rheumatoid arthritis:its role and the inhibition of its activation by nonsteroidal antiinflammatory drugs. Semin Arthritis Rheum. 1983 ; 13 (1 Suppl 1) : 148-53.
103. Buch M H, Emery P.New therapies in the management of rheumatoid arthritis. Curr Opin Rheumatol. 2011 ; 23 (3) : 245-51.
104. Passalacqua G , Ciprandi G , Scordamaglia A , Canonica G W.A ntileukotriene agents:rationale for and prospects of use. Ann Ital Med Int. 1996 ; 11 (Suppl 2) : 93S-6S.
105. Anderson GD , Keys KL , Ciechi PA , Masferrer JL. Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis. Inflamm Res. 2009 ; 58 (2) : 109-17.
106. Rainsford K D, Ying C , Smith F.Affects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture:comparison with interleukin-1-synthesis inhibitors. JPharm Pharmacol. 1996 ; 48 (1) : 46-52.
107. Schiff M.Emerging treatments for rheumatoid arthritis. Am J Med. 1997;102(1A):11S-5S.
108. A mmon H P.Boswellic acids (components of frankincense) as the active principle in treatment of chronic inflammatory diseases. Wien Med Wochenschr. 2002 ; 152 (15-16) : 373-8.
109. Poeckel D , Werz O.Boswellic acids:biological actions and molecular targets. Curr Med Chem. 2006 ; 13 (28) : 3359-69.
110. Cuaz-Perolin C , Billiet L , Bauge E , Copin C , Scott-Algara D , Genze F , et al. Antiinflammatory and antiatherogenic effects of the NF-kappaB inhibitor acetyl-11-keto-beta-boswellic acid in LPS-challenged ApoE-/-mice. Arterioscler Thromb Vasc Biol. 2008 ; 28 (2) : 272-7.
111. Takada Y , Ichikawa H , Badmaev V , Aggarwal B B.A cetyl-11-ketobeta- boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-kappa B and NF-kappa B-regulated gene expression. JImmunol. 2006 ; 176 (5) : 3127-40.
112. Tsuji F , Miyake Y , Horiuchi M , Mita S.Involvement of leukotriene B4 in murine dermatitis models. Biochem Pharmacol. 1998 ; 55 (3) : 297-304.
113. Rask-Madsen J , Bukhave K , Laursen LS , Lauritsen K.5-Lipoxygenase inhibitors in the treatment of inflammatory bowel disease. Adv Prostaglandin Thromboxane Leukot Res. 1994 ; 22 : 113-24.
114. Datta K , Biswal SS , Kehrer JP. The 5-lipoxygenase-Activating protein (FLAP) inhibitor, MK886, induces apoptosis independently of FLAP. Biochem J.1999 ; 340 (Pt 2) : 371-5.
115. Fretland DJ , Anglin CP , Bremer M , Isakson P , Widomski DL , Paulson SK , et al. Antiinflammatory effects of second-generation leukotriene B4 receptor antagonist, SC-53228:impact upon leukotriene B4-And 12(R)-HETE-mediated events. Inflammation. 1995 ; 19 (2) : 193-205.
116. Griffiths RJ , Pettipher ER , Koch K , Farrell CA , Breslow R , Conklyn MJ , et al. Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis. Proc Natl Acad Sci USA. 1995 ; 92 (2) : 517-21.
117. Dunn CJ , Goa KL. Zafirlukast:An update of its pharmacology and therapeutic efficacy in asthma. Drugs. 2001 ; 61 (2) : 285-15.
118. Bonnet C , Bertin P , Cook-Moreau J , Chable-Rabinovitch H , Treves R , Rigaud M.Lipoxygenase products and expression of 5-lipoxygenase and 5-lipoxygenase-Activating protein in human cultured synovial cells. Prostaglandins. 1995 ; 50 (3) : 127-35.
119. Rola-Pleszczynski M , Bouvrette L , Gingras D , Girard M.Identification of interferon-gamma as the lymphokine that mediates leukotriene B4-induced immunoregulation. JImmunol. 1987 ; 139 (2) : 513-7.
120. Leppert D , Hauser SL , Kishiyama JL , An S , Zeng L , Goetzl EJ. Stimulation of matrix metalloproteinase-dependent migration of T cells by eicosanoids. FASEB J.1995 ; 9 (14) : 1473-81.
121. Grespan R , Fukada S Y, Lemos H P, Vieira S M, Napimoga M H, Teixeira MM , et al. CXCR2-specific chemokines mediate leukotriene B4-dependent recruitment of neutrophils to inflamed joints in mice with antigen-induced arthritis. Arthritis Rheum. 2008 ; 58 (7) : 2030-40.